Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Reply to J.-G. Wang et al

Carlos Rodriguez-Galindo1, Mark Krailo1, Alberto Pappo1

  • 1Carlos Rodriguez-Galindo, MD, Department of Oncology, St Jude Children's Research Hospital, Memphis, TN, Department of Global Pediatric Medicine, St Jude Children's Research Hospital, Memphis, TN; Mark Krailo, PhD, Statistics and Data Center, Children's Oncology Group, Monrovia, CA, Department of Preventive Medicine, University of Southern California, Los Angeles, CA; and Alberto Pappo, MD, and Raul Ribeiro, MD, Department of Oncology, St Jude Children's Research Hospital, Memphis, TN.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|July 6, 2021
PubMed
Summary

No abstract available in PubMed .

Related Experiment Videos

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Educational Interventions for the Timely Diagnosis of Pediatric Patients With Cancer: A Scoping Review.

JCO global oncology·2026
Same author

Landscape Assessment to Characterize Baseline Access and Multilevel Barriers to IMProve Access to Chimeric Antigen Receptor T-Cell CD19 Therapy for Pediatric B-ALL (IMPACT study) Across Europe.

JCO global oncology·2026
Same author

Outcomes following radiotherapy for atypical teratoid/rhabdoid tumor in combination with surgery and intensive chemotherapy: A report from Children's Oncology Group study ACNS0333.

Neuro-oncology pediatrics·2026
Same author

Clofarabine for relapsed/refractory Langerhans cell (LC) and non-LC histiocytosis.

Blood advances·2026
Same author

Gilteritinib and chemotherapy in children with relapsed/refractory FLT3-ITD AML: results from the phase 1/2 SKIPPER trial.

Blood advances·2026
Same author

Disease extent, not lesion location, determines relapse risk in single-system skeletal Langerhans cell histiocytosis.

Blood advances·2026